This study aims to assess the effects of six months of standard cardiac rehabilitation provision and concurrent treatment with dapagliflozin in post-CABG patients with type-2 diabetes mellitus or elevated glycated hemoglobin indicative of prediabetes in the presence or absence of chronic kidney disease and the effect of the SGLT2 inhibitor on the ischemic risk (H-FABP and troponin levels) in CABG patients undergoing cardiac rehabilitation. Here, FABP3 is linked to chronic kidney disease.